Clinical Trial

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What is the best dose of BPX-601 * How well BPX-601 may work to destroy prostate cancer
Protocol Amendment History 4 changes
critical Recruitment opened 2026-07-01
notable Primary completion pushed: 2029-12-31 -> 2030-02-05 2026-07-01
minor Completion pushed: 2031-03-20 -> 2031-04-25 2026-07-01
minor Completion pushed: 2030-11-04 -> 2031-03-20 2026-05-30
Trial Details
NCT Number NCT07543055
Lead Sponsor Regeneron Pharmaceuticals
Conditions Prostate Cancer
Enrollment 36 participants
Start Date 2026-08-10
Primary Completion 2030-02-05 (estimated)
Study Completion 2031-04-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-10